{
  "abstract": "Neoadjuvant immunotherapy may improve long-term outcomes by activating antitumor immunity before surgery. We evaluated danburstotug (IMC-001), an anti–PD-L1 antibody, in resectable gastric cancer (GC), esophageal squamous cell carcinoma (ESCC), and hepatocellular carcinoma (HCC). In this phase II trial, patients received two cycles of danburstotug (20 mg/kg every 2 weeks) before surgery. The primary endpoint was major pathologic response (MPR, <10% viable tumor). Key secondary endpoints included safety, radiologic/metabolic response, survival outcomes, and translational immune profiling. Forty-eight patients were evaluable (16 per cohort). The study did not meet its pre-specified primary endpoint, with MPR achieved in 2/48 patients (4.2%)—one ESCC and one HCC (6.3% per cohort). However, pathologic tumor regression to ≤50% viable tumor was observed in 11/48 patients (22.9%; GC 25.0%, ESCC 31.3%, HCC 12.5%). Among evaluable patients, partial responses were observed radiographically in 17.6% and metabolically in 23.3%. Treatment was well tolerated, with grade ≥3 treatment-related adverse events in 6.0% and no grade 4–5 events; two surgical delays were observed, of which one was treatment-related. All patients underwent surgery with R0 resection. Immune profiling revealed cancer type-specific immune-remodeling. Neoadjuvant danburstotug was safe, did not compromise surgical outcomes, and provided exploratory insights into treatment-induced immune microenvironment remodeling. ClinicalTrials.gov ID: NCT04196465, date of registration: August 28, 2019.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea",
    "Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea",
    "BK21 Graduate Program, Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea",
    "Department of Liver Transplantation and Hepatobiliary Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea",
    "Department of Stomach Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea",
    "Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea",
    "Department of Thoracic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea",
    "Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea",
    "Biomedical Research Center, Asan Medical Center, Seoul, Republic of Korea",
    "Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea",
    "PrismCDX Co., Ltd., Hwaseong-si, Gyeonggi-do, Republic of Korea"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 25,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Yeong Hak Bang"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Dawon Kang"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Seungwon Lee"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Seungsoo Kim"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Ina Jeon"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Eunjin Park"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Jungmin Choi"
    },
    {
      "affs": [
        3
      ],
      "name": "Gi-Won Song"
    },
    {
      "affs": [
        4
      ],
      "name": "Moon-Won Yoo"
    },
    {
      "affs": [
        5
      ],
      "name": "Joon Seon Song"
    },
    {
      "affs": [
        5
      ],
      "name": "In Hye Song"
    },
    {
      "affs": [
        6
      ],
      "name": "Yong-Hee Kim"
    },
    {
      "affs": [
        6
      ],
      "name": "Hyeong Ryul Kim"
    },
    {
      "affs": [
        7
      ],
      "name": "Ho June Song"
    },
    {
      "affs": [
        7
      ],
      "name": "Do Hoon Kim"
    },
    {
      "affs": [
        7
      ],
      "name": "Kee Don Choi"
    },
    {
      "affs": [
        7
      ],
      "name": "Jeong Hoon Lee"
    },
    {
      "affs": [
        7
      ],
      "name": "Ji Yong Ahn"
    },
    {
      "affs": [
        7
      ],
      "name": "Ju Hyun Shim"
    },
    {
      "affs": [
        7
      ],
      "name": "Danbi Lee"
    },
    {
      "affs": [
        7
      ],
      "name": "Jonggi Choi"
    },
    {
      "affs": [
        8
      ],
      "name": "Ji Eun Kim"
    },
    {
      "affs": [
        9
      ],
      "name": "Sang-Yeob Kim"
    },
    {
      "affs": [
        10
      ],
      "name": "Dong-Jun Bae"
    },
    {
      "affs": [
        0
      ],
      "name": "Sook Ryun Park"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/e120vvbr8nncp.bib",
  "cited_by": 0,
  "doi": "10.1038/s41698-026-01571-2",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13696679/",
  "id": "e120vvbr8nncp",
  "issns": [
    "2397-768X"
  ],
  "landing_url": "https://doi.org/10.1038/s41698-026-01571-2",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Article"
    ],
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7167255435",
  "pdf_url": "https://www.nature.com/articles/s41698-026-01571-2_reference.pdf",
  "pmcid": "PMC13696679",
  "pmid": "42399382",
  "published": "2026-07-03",
  "publisher": "Nature Publishing Group",
  "ris": "https://research.draconitic.com/paper/e120vvbr8nncp.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:59Z",
      "native_id": "PMC13696679",
      "source": "pmc",
      "url": "https://doi.org/10.1038/s41698-026-01571-2"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Immunotherapy and Biomarkers",
      "subfield": "oncology"
    }
  ],
  "title": "Neoadjuvant Danburstotug (IMC-001) therapy in gastric, esophageal, and hepatocellular carcinoma: the NeoChance phase II study",
  "title_text": "Neoadjuvant Danburstotug (IMC-001) therapy in gastric, esophageal, and hepatocellular carcinoma: the NeoChance phase II study",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:33:58Z",
  "url": "https://research.draconitic.com/paper/e120vvbr8nncp",
  "venue": "NPJ Precision Oncology",
  "versions": []
}